Objective: To present observations on administration of natalizumab to 18 patients with the comorbid MS and psoriasis, who represented a full subset of patients with such comorbidity within the patient records available.
Methods: A retrospective analysis of patient records was performed. Patient histories were gathered and included date of diagnosis of MS and psoriasis, MS disease-modifying therapies (DMTs), Expanded Disability Status Scale (EDSS), reason for DMT switch, and effects on MS and psoriasis status.
Results: On initiation of natalizumab, all 18 patients had a complete cessation of MS disease activity (within 2-8 months) with significant patient-reported improvement of psoriasis (within 1-5 months). This improvement was independent of previous MS therapy and led to 15 of 18 patients needing no additional treatment for MS and psoriasis (remaining 3 patients continued to use topical treatments for psoriasis).
Conclusions: In this cohort of 18 patients with comorbid MS and psoriasis, beneficial results on both diseases were observed after initiation of therapy with natalizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057059 | PMC |
| http://dx.doi.org/10.1212/NXI.0000000000000961 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical features of inflammatory arthritis in daily practice-China's perspective.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.
Objective: This study aimed to analyze and compare the proportion of patients with different types of inflammatory arthritis and investigate the clinical characteristics, including symptoms and signs, medication choices, and disease activity, in the daily clinical practice of China.
Methods: Patients with inflammatory arthritis were recruited from 16 Grade-A tertiary hospitals between August 2021 and April 2022. The medical profiles, encompassing sociodemographic characteristics, clinical and laboratory date, were collected.
Immunoglobulin E, the potential accelerator of comorbid psoriasis and atherosclerosis.
Biomed Pharmacother
January 2025
Laboratory of Medical Mycology & Department of Dermatology, Jining No.1 People's Hospital affiliated to Shandong First Medical University, Jining, Shandong, China. Electronic address:
Immunoglobulin (Ig) E is a key mediator in the induction and maintenance of allergic inflammation, characterized by a Th2-dominated immune response. Recently epidemiological studies have showed that elevated serum total IgE levels or an increased abundance of mast cells (MCs) at the lesion site are observed in psoriatic patients with cardiovascular diseases (CVD), such as atherosclerosis. Although the underlying mechanisms by which IgE synergizing with MCs in promoting these chronic immune-inflammatory diseases remain unclear, the interleukin (IL)-23/IL-17 axis appears to play a crucial role in comorbidity of psoriasis and atherosclerosis.
View Article and Find Full Text PDFClinical aspects of psoriatic arthritis: one year in review 2024.
Clin Exp Rheumatol
January 2025
Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa, Italy.
Psoriatic arthritis is a very pleomorphic inflammatory disease characterised by its association with psoriasis and the development of a wide spectrum of comorbidities that can impact patients' prognosis and quality of life.In recent years, several new drugs have been developed, showing significant efficacy in alleviating symptoms and signs, while maintaining a generally favourable safety profile. Despite these advancements, the management of PsA remains potentially suboptimal.
View Article and Find Full Text PDFGlobal Delphi consensus on treatment goals for generalised pustular psoriasis.
Br J Dermatol
January 2025
Department of Dermatology, Yale University, New Haven, CT, USA.
Background: Generalised pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease. A previous Delphi panel established areas of consensus on GPP, although patient perspectives were not included, and aspects of treatment goals remain unclear.
Objectives: To identify and achieve consensus on refined, specific treatment goals for GPP treatment via a Delphi panel with patient participation.
Clinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database.
J Dermatol
January 2025
Department of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Vitiligo is a chronic autoimmune disorder that profoundly impacts patients' quality of life. Real-world data on vitiligo in Japan are limited. This descriptive, cross-sectional study used a claims database to evaluate vitiligo prevalence, patient demographics, treatments, and comorbidities in Japanese patients with vitiligo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!